[Federal Register Volume 64, Number 93 (Friday, May 14, 1999)]
[Notices]
[Pages 26421-26422]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-12204]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Government-Owned Inventions; Availability for Licensing
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (DHHS).
ACTION: Notice.
-----------------------------------------------------------------------
The inventions named in this notice are owned by agencies of the
United States Government and are available for licensing in the United
States (U.S.) in accordance with 35 U.S.C. 207 to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for U.S. companies and may also be
available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to Thomas E.
O'Toole, M.P.H., Deputy Director, Technology Transfer Office, Centers
for Disease Control and Prevention (CDC), Mailstop E-67, 1600 Clifton
Rd., Atlanta, GA 30333, telephone (404) 639-6270; facsimile (404) 639-
6266. Please note that a signed Confidential Disclosure Agreement will
be required to receive copies of the patent applications.
Oligonucleotide Probes for Detecting Enterobacteriaceae and
Quinolone-ResistantEnterobacteriaceae
Specific oligonucleotide probes have been developed to be
incorporated into methods for the species-specific identification of
these Enterobacteriaceae in a sample as well as detection and diagnosis
of Enterobacteriaceae infection in a subject. This invention further
provides methods for species-specific identification of these
quinolone-resistant Enterobacteriaceae as well as the detection and
diagnosis thereof.
Inventor: Linda M Weigel, et al.
U.S. Patent Application SN: 60/080,375 (CDC Ref. #: I-003-98/0)
Compositions and Methods for Detecting Adult Taenia Solium
Compositions and methods for the detection of adult Taenia solium
and the diagnosis and treatment of T. solium infection are described.
The compositions contain one or more adult T. solium polypeptides which
can be useful as diagnostic agents for the detection of adult tapeworm
infection.
Inventor: Victor Tsang, et al.
U.S. Patent Application SN: 60/111,334 (CDC Ref. #: I-028-97/0)
Recombinant Multi-Valent Malarial Vaccine
This invention relates generally to the development and use of a
recombinant, multi-valent and multi-stage malaria vaccine and more
specifically relates to an antigenic protein useful for preventing or
treating P. falciparum malarial infections. The invention further
provides a vaccine against malaria that is effective in inhibiting
reproductive growth of the parasite within a human or animal after
initial infection. Also, this invention provides a method for
conferring immunity against different stages in the life cycle of the
malarial parasite, P. falciparum. Furthermore, the invention includes
antibodies against a recombinant protein containing antigenic epitopes
to various stages of a malarial Plasmodium species that may be useful
as research or diagnostic reagents for the detection and measurement of
P. falciparum in a biological sample.
Inventor: Altaf A. Lal, et al.
U.S. Patent Application SN: 60/097,703 (CDC Ref. #: I-004-98/0)
Reagent and Method for Detecting Cryptosporidium Parvum Oocysts
A reagent and method for the specific and highly sensitive
detection of C. parvum in which the reagent is an antibody for a
soluble C. parvum sporozoite antigen. The method comprises of an
immunoassay in which the antibody is used to detect or quantify C.
parvum sporozoite in a sample. The assay allows recognition and
detection of C. parvum in turbid samples. And since there exists a lack
of crossreactivity with other Cryptosporidium species, the assay is
also highly specific for C. parvum contamination or infection.
Inventor: Victor Tsang, et al.
U.S. Patent Application SN: 60/111,225 (CDC Ref. #: I-039-98/0)
Isolation of a New Human Retrovirus
A new isolate of a human retrovirus has been identified in several
cases of foamy virus infection in persons at risk for this occupational
exposure to simian retroviruses. This new isolate demonstrates a number
of phenotypic differences from previously isolated foamy viruses by its
immune reactivity, cell tropism, cytopathcity and growth kinetics. Due
to its human-derived/adapted nonpathogenic nature, this new isolate may
be suitable as a potential gene therapy vector.
Inventor: Paul A. Sandstrom
U.S. Patent Application SN: 60/105,811 (CDC Ref. #: I-034-97/0)
Methods and Compositions for the Detection of Human Herpesvirus
Methods and compositions for the detection and diagnosis of
infectious diseases are provided. In particular, efficient and
sensitive compositions and methods for the detection of human
herpesvirus 8 are provided. The diagnostic compositions and methods of
the invention involve the use of peptides representative of dominant
antigenic regions of human herpesvirus in detection assays. Such assays
are highly specific, sensitive and accurate.
Inventor: Chou-Pong Pau
U.S. Patent Application SN 60/086,695 (CDC Ref. #: I-018-98/0)
Methods and Reagents for Molecular Detection of HIV-1 Groups M, N,
and O
This invention provides reagents and assays for detecting HIV-1
groups M and O and optionally HIV-1 group N and SIVcpz. Nucleic acid
primers for the hybridization to, amplification and subsequent
detection are also provided for. The nucleic acid amplification assays
can detect small concentrations of HIV and are also useful for
qualitative and quantitative examinations.
Inventor: Renu B. Lal, et al.
U.S. Patent Application SN: 60/118,357 (CDC Ref. #: I-020-98/0)
Nucleic Acid Vaccines for the Prevention of Flavivirus Infection
This novel vaccine for flaviviruses comprises of recombinant
nucleic acids that contain genes for structural proteins of
flaviviruses, such as Japanese encephalitis virus (JEV). These vaccines
serve as a transcriptional unit for the biosynthesis of the virus
protein antigens when administered in vivo. Furthermore, the invention
provides for a method of immunizing a subject against infection by a
flavivirus.
[[Page 26422]]
Inventor: Gwong-Jen J. Chang
U.S. Patent Application SN: 60/087,908 (CDC Ref. #: I-008-97/0)
Method and Devices for Detection of Retroviral Infection
This invention comprises of methods, devices and compositions for
detection of endogenous retroviruses found in xenotransplant materials.
The methods and compositions are suited for detection of endogenous
type-C retroviruses and in particular, for porcine endogenous
retrovirus (PERV). Detection of such is necessary following
xenotransplantation of porcine cellular products.
Inventor: Walid Heneine, et al.
U.S. Patent Application SN 60/090,972 (CDC Ref. #: I-021-98/0)
Methods and Devices for Detection of Xenogeneic Infectious Agents
Compositions, methods and diagnostic devices for monitoring porcine
graft integrity and detecting the presence of porcine endogenous
retrovirus (PERV) in a biological sample. The compositions, methods and
devices are useful for determining or monitoring graft survival and
rejection in recipients of xenografts and are useful for detecting PERV
infections in a xenotransplant recipient or donor. In addition, the
compositions, methods and devices are useful for screening therapeutic
products to be administered to humans to ensure that the products are
free of PERV contamination prior to administration.
Inventor: Bill Switzer, et al.
U.S. Patent Application SN: 60/093,202 (CDC Ref. #: I-024-98/0)
Associated U.S. Patent Application SN: 60/098,262 (CDC Ref. #: I-024-
98/1)
Methods for the Prevention and Treatment of Diseases Caused by an
Inflammatory Response
This invention provides methods for preventing or treating a
disease in a subject caused by an inflammatory response to a disease or
syndrome that is mediated by endogenous substance P. The methods
include administration of anti-substance P antibodies or anti-substance
P antibody fragments.
Inventor: Ralph A. Tripp, et al.
U.S. Patent Application SN: 60/116,835 (CDC Ref. #: I-009-98/0)
13
Preparation and Use of Recombinant Influenza A Virus M2 Constructs
in Vaccines
M2, a structurally conserved influenza A viral surface protein, is
capable of inducing broader, more cross-reactive immunity to type A
influenza viruses. This invention solves the problems of the prior art
approaches to recombinant M2 production by providing new recombinant
forms of M2 whose structure has been modified to allow simple
prokaryotic expression as a soluble, readily purified variant protein
which retains antigenic and immunogenic properties. The invention
relates to vaccines comprised of these new recombinant forms of M2, and
to methods of prevention and treatment of influenza A virus infections.
Inventor: A. Michael Frace, et. al.
U.S. Patent Application SN: 08/906,930 (CDC Ref. #: I-020-97/0)
Method and Kit for Detecting Resistance to Antiviral Drugs
One of the problems with the development of current therapies for
HIV infection is that the HIV virus rapidly develops resistance to
drugs such as reverse transcriptase inhibitors. This invention provides
for an assay and kit for the detection of phenotypic resistance to a
reverse transcriptase inhibitor drug in a biological sample.
Inventor: Walid Heneine, et al.
U.S. Patent Application SN: 60/090,051 (CDC Ref. #: I-005-98/0)
Novel Granulocytic Ehrlichia Genes and Uses Thereof
Granulocytic ehrlichiosis is an acute, potentially fatal tick-borne
infection. This invention provides for granulocytic ehrlichia specific
genes encoding thirteen proteins that can be used as diagnostic
reagents and vaccines. Isolated nucleic acid molecules, purified
polypeptides, nucleic acid probes, and antibodies to the thirteen
proteins are provided for. The recombinant nucleic acid molecule,
vectors, cells and many other forms of the molecule are provided for
along with the methods and kit for detection.
Inventor: Cheryl I. Murphy, et al.
U.S. Patent Application SN: 09/178,316 (CDC Ref. #: I-011-99/0)
Invasion Associated Genes from Neisseria Meningitidis Serogroup B
The invention provides nucleic acids and encoded polypeptides
associated with invasion of Neisseria meningitidis. The polypeptides
are used as diagnostic reagents, as immunogenic reagents, and as
components of vaccines. The nucleic acids are used as diagnostic
reagents, as components of vectors and vaccines, and to encode the
polypeptides of the invention. The invention also provides strains of
Neisseria meningitidis which have an invasion deficient phenotype.
Inventors: Frederick D. Quinn, et. al.
U.S. Patent Application SN: 60/030,432 (Ref. #: I-002-95/0)
Dated: May 10, 1999.
Joseph Carter,
Acting Associate Director for Management and Operations, Centers for
Disease Control and Prevention (CDC).
[FR Doc. 99-12204 Filed 5-13-99; 8:45 am]
BILLING CODE 4163-18-P